Castle Biosciences Chief Business Officer resigns; enters consulting agreement with vesting extension

CASTLE BIOSCIENCES INC

Bernhard Spiess resigns as CBO effective Dec 31, 2021; separation agreement signed Dec 29, 2021.
Receives accrued salary ($16,666.67), PTO payout ($72,783.74), and 2021 bonus (50% salary × board-approved corp attainment).
Consulting agreement at $250/hour through Dec 31, 2022; outstanding equity continues vesting during consulting term.
Non-competition for 1 year and non-solicitation for 3 years after consulting ends.
Company may terminate consulting agreement immediately for any reason.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Bernhard E. Spiess

Chief Business Officer

CSTL · CASTLE BIOSCIENCES INC

Effective: 2021-12-31
Filed: January 5, 2022, 6:59 PM ET

Bernhard E. Spiess, former Chief Business Officer of Castle Biosciences, Inc. (the “Company”), notified the Company of his intention to resign effective as of December 31, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bernhard E. Spiess resigned as Chief Business Officer at CASTLE BIOSCIENCES INC.

Action: resigned
Role: Chief Business Officer

Exact text from the filing

Bernhard E. Spiess, former Chief Business Officer of Castle Biosciences, Inc. (the “Company”), notified the Company of his intention to resign effective as of December 31, 2021.

View on SEC.gov

CASTLE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0001447362-22-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.